Stock Analysis

Dyadic International And 2 Other US Penny Stocks To Watch

Published

The U.S. stock market recently experienced a significant downturn, with major indices like the Dow Jones Industrial Average and the S&P 500 suffering their worst one-day losses in months due to concerns over interest rate policies. In this context, investors might consider exploring alternative investment areas such as penny stocks, which remain a relevant opportunity despite being considered somewhat niche today. These stocks often represent smaller or newer companies and can offer substantial growth potential when supported by strong financial foundations.

Top 10 Penny Stocks In The United States

NameShare PriceMarket CapFinancial Health Rating
Inter & Co (NasdaqGS:INTR)$3.95$1.93B★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)$3.08$108.87M★★★★★★
BAB (OTCPK:BABB)$0.905$6.59M★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)$2.78$87.36M★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)$4.50$67.38M★★★★★★
Permianville Royalty Trust (NYSE:PVL)$1.445$47.52M★★★★★★
CBAK Energy Technology (NasdaqCM:CBAT)$0.80$77.26M★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)$0.9632$17.69M★★★★★☆
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)$1.30$65.6M★★★★★☆
Safe Bulkers (NYSE:SB)$3.58$381.2M★★★★☆☆

Click here to see the full list of 739 stocks from our US Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Dyadic International (NasdaqCM:DYAI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Dyadic International, Inc. is a biotechnology platform company that develops, produces, and sells enzymes and other proteins both in the United States and internationally, with a market cap of $42.90 million.

Operations: The company generates its revenue primarily from its biotechnology segment, amounting to $3.36 million.

Market Cap: $42.9M

Dyadic International, Inc., a biotechnology company with a market cap of US$42.90 million, reported significant revenue growth for the third quarter of 2024, reaching US$1.96 million from US$0.40 million the previous year. Despite this increase, the company remains unprofitable with a negative return on equity and is not expected to achieve profitability in the near term. Dyadic has more cash than debt and maintains sufficient cash runway for over a year at current free cash flow levels. However, shareholders have experienced dilution recently due to an increase in shares outstanding by 2.7%.

NasdaqCM:DYAI Revenue & Expenses Breakdown as at Dec 2024

WM Technology (NasdaqGS:MAPS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: WM Technology, Inc. offers ecommerce and compliance software solutions for retailers and brands in the cannabis market both in the United States and internationally, with a market cap of approximately $204.40 million.

Operations: The company generates revenue of $183.31 million from its Software & Programming segment, serving the cannabis market.

Market Cap: $204.4M

WM Technology, Inc., with a market cap of US$204.40 million, is navigating challenges typical for penny stocks. Despite reporting US$183.31 million in revenue from its software solutions for the cannabis sector, the company remains unprofitable with increasing losses over five years. It trades significantly below estimated fair value, presenting potential opportunities but also risks due to high volatility and legal issues concerning inflated user metrics. Recent leadership changes include appointing a new CTO and CFO amidst ongoing class action lawsuits and Nasdaq compliance pressures regarding its stock price. The company's cash runway supports operations for over three years despite shrinking free cash flow.

NasdaqGS:MAPS Revenue & Expenses Breakdown as at Dec 2024

FREYR Battery (NYSE:FREY)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: FREYR Battery, Inc. provides battery solutions in the United States, Norway, and internationally with a market cap of $247.26 million.

Operations: No revenue segments have been reported.

Market Cap: $247.26M

FREYR Battery, Inc., with a market cap of US$247.26 million, is a pre-revenue company navigating the challenges typical for penny stocks. It has no debt and its short-term assets of US$199.5 million comfortably cover both short- and long-term liabilities. However, it remains unprofitable with increasing losses over the past five years and significant insider selling recently observed. The company's management team is new, reflecting recent executive changes including the appointment of Daniel Barcelo as CEO following Tom Einar Jensen's resignation. Despite volatility in share price, FREYR secured a €122 million EU grant for its Finnish project development efforts.

NYSE:FREY Debt to Equity History and Analysis as at Dec 2024

Key Takeaways

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com